School of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
School of Chinese Classics, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
BMJ Open. 2020 Jun 21;10(6):e034554. doi: 10.1136/bmjopen-2019-034554.
Opioid use disorder (OUD) is a worldwide health problem. Clinical trials indicated that acupuncture combined with medication is effective in OUD, however, there are different conclusions presented by previous trials. This study is designed to evaluate the efficacy and safety of acupuncture combined with medication in OUD.
PubMed, CENTRAL, Embase, Web of Science, CINAHL, PsycINFO, ProQuest Dissertation and Theses, AMED, OpenGrey, Clinicaltrials.gov and who.int/trialsearch will be searched in September 2019 without a language restriction. Randomised controlled trials (RCTs) and quasi-RCTs which included participants with OUD receiving acupuncture therapy combined with medication versus control group will be included in this study. Two reviewers will independently screen studies, extract data, assess risk of bias by the Cochrane risk of bias assessment tool and assess quality of evidence by Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Any disagreements will be arbitrated by the third reviewer. Data synthesis and analysis will be conducted by using RevMan V.5.3. Subgroup analyses, sensitivity analysis, meta-regression and reporting bias assessment will be conducted if necessary and appropriate.
On account of the nature of this systematic review and meta-analysis, ethical approval is not required. The results will be published in a peer-reviewed journal.
CRD42019123436.
阿片类药物使用障碍(OUD)是一个全球性的健康问题。临床试验表明,针灸联合药物治疗 OUD 有效,但之前的试验结果存在不同的结论。本研究旨在评估针灸联合药物治疗 OUD 的疗效和安全性。
本研究将于 2019 年 9 月对PubMed、CENTRAL、Embase、Web of Science、CINAHL、PsycINFO、ProQuest Dissertations & Theses、AMED、OpenGrey、Clinicaltrials.gov 和 who.int/trialsearch 进行无语言限制的检索,纳入 OUD 患者接受针灸联合药物治疗与对照组的随机对照试验(RCT)和准随机对照试验。两名评审员将独立筛选研究、提取数据,使用 Cochrane 偏倚风险评估工具评估偏倚风险,并使用推荐评估、制定与评价(GRADE)方法评估证据质量。任何分歧将由第三名评审员裁决。如果需要和适当,将使用 RevMan V.5.3 进行数据综合和分析。将进行亚组分析、敏感性分析、meta 回归和报告偏倚评估。
由于本系统评价和荟萃分析的性质,不需要伦理批准。研究结果将发表在同行评议的期刊上。
PROSPERO 注册号:CRD42019123436。